"The new BD COVID-19 test for the BD MAX System will help increase availability of these much-needed tests around the world," said Dave Hickey, president of Integrated Diagnostics for BD, in April. The FDA is encouraging any and all health care providers to report suspected adverse experiences related to tests using the BD SARS-CoV-2 Reagents for the BD Max System and says it is “working with Becton, Dickinson and Company (BD) to resolve this issue.” "We continue to work towards a full portfolio of testing options to give health care workers choice and access to the right test for the right situation."Īccording to the FDA, the test is designed to detect viral nucleic acid from the virus that causes COVID-19 in upper respiratory specimens, such as nasal swabs. RELATED: Amid coronavirus spikes, COVID-19 testing demand is outpacing capacity, major test providers warn The news comes as the demand for coronavirus testing in the U.S. is beginning to outpace the supply, according to a warning by major test providers. On June 29, Quest Diagnostics, one of the nation’s leading medical testing companies, which completed more than 5 million COVID-19 diagnostic tests in June, announced that it was overwhelmed by the surging demand for coronavirus-related services.Īs a result of the high demand, the company said it is currently only providing single-day turnaround for coronavirus test results for hospitalized patients only.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |